Peptide library › Heart & blood
Rusfertide
Also known as Mimrylo, PTG-300
Weekly injection that mimics the iron hormone hepcidin to control red blood cell overproduction in polycythemia vera.
What people use it for
- Polycythemia vera in adults
What Rusfertide does in the body
Mimics hepcidin, the body's master iron regulator. Limiting iron available to the bone marrow slows red blood cell production, reducing the need for blood removal (phlebotomy).
Strength of evidence
Strong: the Phase 3 VERIFY trial cut the need for phlebotomy versus placebo.
Look up the evidence
- Reviews on PubMed: Summaries of the published research
- Clinical trials on PubMed: Published studies in people
- ClinicalTrials.gov: Registered trials, past and ongoing
- Prescribing information (DailyMed, US): Official US label
- Patient leaflets (emc, UK): Official UK product information
Live searches of official databases. New to the terms? See the glossary.
Reported side effects & risks
- Injection-site reactions
- Tiredness
- Long-term effects still being followed
Who should avoid it or take extra care
- Pregnancy or breastfeeding, unless a specialist advises it
- Anyone without polycythemia vera
Not a complete list. Check with a doctor or pharmacist about your own health and medicines.
Regulatory status
FDA-approved on 28 August 2026 as Mimrylo, the first approved hepcidin mimetic. Prescription only.
How it's taken
Route: Injection under the skin, once weekly
How long it lasts (half-life): Long-acting; supports weekly dosing
Keep track of Rusfertide privately
Fiala is a free app for logging doses, tracking vials and setting reminders. No account, and everything you log stays on your phone.
Open Rusfertide in Fiala How to installMore in Heart & blood
- EnlicitideFirst daily tablet that blocks PCSK9 to lower LDL ("bad") cholesterol, a job that previously needed injections.
- Angiotensin IIIntensive-care drip that raises dangerously low blood pressure in shock when other drugs aren't enough.
- BivalirudinShort-acting blood thinner given by drip during heart procedures such as stenting.
- DesirudinLab-made leech-derived blood thinner once used to prevent clots after hip replacement; now discontinued in the US.
- EptifibatideHospital drip that stops platelets clumping during heart attacks and stenting.
- NesiritideLab-made heart hormone (BNP) once used by drip for sudden heart failure; now largely withdrawn.
- VasopressinNatural hormone given by drip in intensive care to raise blood pressure in shock.
- SelepressinExperimental vasopressin-like drug for septic shock that failed its main trial.
- DesmopressinSynthetic version of the water-retaining hormone, used for bedwetting, frequent night-time urination, diabetes insipidus and some bleeding disorders.
- TerlipressinHospital drug that improves kidney function in hepatorenal syndrome, a kidney failure caused by severe liver disease.
- PegcetacoplanComplement blocker used for the rare blood disease PNH (as an infusion under the skin) and for geographic atrophy in the eye (as an eye injection).